elongin C pseudogene 3Genealiases: TCEB1P3 · dJ254P11.1
Q-omics provides the consensus-scored ELOCP3 profile across patient tissues and cancer cell-line models. ELOCP3 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, ELOCP3 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, ELOCP3 RNA expression shows 5,940 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, THCA, and STAD as cancer lineages where ELOCP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP3 survival associations across molecular data types. ELOCP3 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP3 RNA expression–survival associations across cancer types. High ELOCP3 expression shows unfavorable associations in THYM, ESCA and GBM, but favorable associations in SKCM, MESO and PAAD. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify THYM as the clearest survival context for ELOCP3 RNA expression.
This table summarizes ELOCP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP3 shows lower tumor expression in THCA and LIHC and higher tumor expression in KIRC. The THCA box plot shows higher ELOCP3 RNA expression in normal versus tumor tissue (log2 FC = −0.054, t-test p = .008).
This table shows molecular features associated with ELOCP3 in patient tissues and cancer cell lines. In patient samples, ELOCP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
